Table 1 The antibiotic-resistanceof the two groups {carbapenem-resistant E.coli (CREC) and carbapenem-susceptible E.coli (CSEC)}
|  | Case (n = 49) | Control (n = 98) | p |
|---|---|---|---|
Ampicillin | 47/47 (100%) | 90/96 (94%) | 0.08 |
Piperacillin/tazobactam | 38/48 (79%) | 10/96 (10%) | 0.00 |
Ampicillin/sulbactam | 40/40 (100%) | 75/88 (85%) | 0.01 |
Cefoperazone/sulbactam | 29/45 (64%) | 13/96 (14%) | 0.00 |
Cefazolin | 42/42 (100%) | 75/92 (82%) | 0.00 |
Ceftazidime | 37/39 (95%) | 48/87 (55%) | 0.00 |
Ceftriaxone | 47/47 (100%) | 75/97 (77%) | 0.00 |
Cefepime | 49/49 (100%) | 50/96 (52%) | 0.00 |
Cefotetan | 22/31 (71%) | 2/85 (2%) | 0.00 |
Aztreonam | 47/49 (96%) | 62/97 (54%) | 0.00 |
Tobramycin | 26/45 (58%) | 51/94 (54%) | 0.69 |
Amikacin | 3/48 (6%) | 8/98 (8%) | 0.68 |
Gentamicin | 26/48 (54%) | 49/98 (50%) | 0.64 |
Ciprofloxacin | 41/46 (89%) | 64/96 (67%) | 0.00 |
Levofloxacin | 41/49 (84%) | 60/96 (63%) | 0.01 |
Trimethoprim + sulfamethoxaz ole | 36/49 (73%) | 58/96 (60%) | 0.05 |
Nitrofurantoin | 18/44 (41%) | 20/98 (20%) | 0.01 |